Serum Vancomycin Levels in Patients Receiving Enteral Vancomycin
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00617227|
Recruitment Status : Completed
First Posted : February 15, 2008
Last Update Posted : February 10, 2010
The study is based on the hypothesis that decreased creatinine clearance may be associated with detectable vancomycin levels in patients on enteral (oral / vancomycin enemas) vancomyicn for CDAD.
The objective of the study is to see whether enteral vancomycin is absorbed through the inflamed GI mucosa in CDAD, and if it is absorbed, does it achieve measurable serum concentration.
|Condition or disease|
|Clostridium Difficle Colitis Clostridium Difficle Associated Disease|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Measurement of Serum Vancomycin in Patients Receiving Enteral ( Oral/Intracolonic) Vancomycin.|
|Study Start Date :||October 2007|
|Actual Primary Completion Date :||May 2008|
|Actual Study Completion Date :||February 2010|
- Patients with detectable serum vancomycin levels during enteral vancomycin therapy [ Time Frame: 5-7days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00617227
|United States, New York|
|Maimonides Medical Center|
|Brooklyn, New York, United States, 11219|
|Principal Investigator:||Edward K Chapnick, MD||Maimonides Medical Center|